Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...
Fresh from agreeing a wide-ranging alliance with Regeneron worth up to $2.3 billion, Parabilis Medicines has decided to ...
Merck KGaA reported Q1 net income of €669 million, declining 9.4% annually, yet delivered earnings per share of €2.11, surpassing the €1.99 consensus estimate. Quarterly revenue decreased 2.8% to ...
The funding comes from a total of $20 million the provincial government is providing to festivals and tourism organizations ...
If you work in HR, people ops, or talent management, you've probably noticed the same thing everyone else has: there are a lot of tools out there ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a Stamford, Connecticut-based biopharmaceutical company with a market capitalization of $3.52 billion and impressive gross profit margins of 93%, has ...
SpringWorks Therapeutics has established itself as a promising player in the U.S. Small & Mid Cap Biotechnology sector. The company’s primary focus has been on developing innovative therapies for ...
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European ...
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional ...
STAMFORD, Conn. - SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), currently trading at $46.27 with a market capitalization of $3.49 billion, has announced that the European Medicines Agency’s Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results